Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 18/20 | 0.84 |
| ▸ | CDK2 | P24941 | 17/20 | 0.84 |
| ▸ | CDK4 | P11802 | 16/20 | 0.84 |
| ▸ | CCND1 | P24385 | 16/20 | 0.84 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.84 |
| ▸ | CASK | O14936 | 1/20 | 0.84 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.84 |
| ▸ | CDKL5 | O76039 | 1/20 | 0.84 |
| ▸ | STK10 | O94804 | 1/20 | 0.84 |
| ▸ | CDK14 | O94921 | 1/20 | 0.84 |
| ▸ | ABL1 | P00519 | 1/20 | 0.84 |
| ▸ | EGFR | P00533 | 1/20 | 0.84 |
| ▸ | MAK | P20794 | 1/20 | 0.84 |
| ▸ | CDK11B | P21127 | 1/20 | 0.84 |
| ▸ | TTK | P33981 | 1/20 | 0.84 |
| ▸ | CLK1 | P49759 | 1/20 | 0.84 |
| ▸ | CLK2 | P49760 | 1/20 | 0.84 |
| ▸ | CLK3 | P49761 | 1/20 | 0.84 |
| ▸ | GSK3A | P49840 | 1/20 | 0.84 |
| ▸ | GSK3B | P49841 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3522420 | 0.95 | CDK1 (0.77) | CDK1CDK2CDK4CCND1CDK5 | |
| SCHEMBL3521283 | 0.94 | CDK1 (0.75) | CDK1CDK2CDK4CCND1CDK5 | |
| Rg-547 SCHEMBL29644949 | 0.92 | CDK1 (1.00) | CDK1CDK2CDK4CCND1CDK5 | |
| Rg-547 SCHEMBL2397067 | 0.92 | CDK1 (1.00) | CDK1CDK2CDK4CCND1CDK5 | |
| SCHEMBL3520103 | 0.88 | CDK2 (0.68) | CDK1CDK2CDK4CCND1CDK5 | |
| SCHEMBL3520514 | 0.88 | CDK1 (0.68) | CDK1CDK2CDK4CCND1CDK5 | |
| SCHEMBL14530614 | 0.88 | CDK1 (0.68) | CDK1CDK2CDK4CCND1CDK5 | |
| SCHEMBL13403109 | 0.88 | CDK1 (0.68) | CDK1CDK2CDK4CCND1CDK5 | |
| SCHEMBL3518905 | 0.88 | CDK1 (0.66) | CDK1CDK2CDK4CCND1CDK5 | |
| SCHEMBL3522526 | 0.87 | CDK1 (0.91) | CDK1CDK2CDK4CCND1CDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705009-B2 | 4-aminopyrimidine-5-thione derivatives | HOFFMAN-LA ROCHE INC. (US) | 2010-04-27 | — | — | US | claimed |
| EP-1957466-A1 | 4-AMINOPYRIMIDINE-5-THIONE-DERIVATIVES FOR THE TREATMENT OF CANCER | F.HOFFMANN-LA ROCHE AG (CH) | 2008-08-20 | — | — | EP | claimed |
| WO-2007060110-A1 | 4-AMINOPYRIMIDINE-5-THIONE-DERIVATIVES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-31 | — | — | WO | claimed |
| US-20070117821-A1 | 4-Aminopyrimidine-5-thione derivatives | DING QINGJIE | 2007-05-24 | — | — | US | claimed |
| US-7705009-B2 | 4-aminopyrimidine-5-thione derivatives | HOFFMAN-LA ROCHE INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-7705009-B2 | 4-aminopyrimidine-5-thione derivatives | HOFFMAN-LA ROCHE INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-7705009-B2 | 4-aminopyrimidine-5-thione derivatives | HOFFMAN-LA ROCHE INC. (US) | 2010-04-27 | — | — | US | disclosed |
| EP-1957466-A1 | 4-AMINOPYRIMIDINE-5-THIONE-DERIVATIVES FOR THE TREATMENT OF CANCER | F.HOFFMANN-LA ROCHE AG (CH) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007060110-A1 | 4-AMINOPYRIMIDINE-5-THIONE-DERIVATIVES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007060110-A1 | 4-AMINOPYRIMIDINE-5-THIONE-DERIVATIVES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-31 | — | — | WO | disclosed |
| US-20070117821-A1 | 4-Aminopyrimidine-5-thione derivatives | DING QINGJIE | 2007-05-24 | — | — | US | disclosed |
| US-20070117821-A1 | 4-Aminopyrimidine-5-thione derivatives | DING QINGJIE | 2007-05-24 | — | — | US | disclosed |
| US-20070117821-A1 | 4-Aminopyrimidine-5-thione derivatives | DING QINGJIE | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117821-A1 | 4-Aminopyrimidine-5-thione derivatives | CDK4, CDK1, CDK2 | CDK1 2/4885CDK2 3/4885CDK4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.